[HTML][HTML] A post-transcriptional program of chemoresistance by AU-rich elements and TTP in quiescent leukemic cells
…, SIA Bukhari, M Boukhali, J Lombardi-Story… - Genome biology, 2020 - Springer
Background Quiescence (G0) is a transient, cell cycle-arrested state. By entering G0, cancer
cells survive unfavorable conditions such as chemotherapy and cause relapse. While G0 …
cells survive unfavorable conditions such as chemotherapy and cause relapse. While G0 …
[PDF][PDF] Single-cell RNA-seq reveals AML hierarchies relevant to disease progression and immunity
…, GK Griffin, S Battaglia, JA Verga, J Stephansky… - Cell, 2019 - cell.com
Acute myeloid leukemia (AML) is a heterogeneous disease that resides within a complex
microenvironment, complicating efforts to understand how different cell types contribute to …
microenvironment, complicating efforts to understand how different cell types contribute to …
Ixazomib in addition to chemotherapy for the treatment of acute lymphoblastic leukemia in older adults
…, A Ramos, M Vartanian, J Lombardi Story… - Leukemia & …, 2022 - Taylor & Francis
We sought to assess the safety of adding ixazomib, an oral proteasome inhibitor, to a multi-agent
treatment regimen for older adults with acute lymphoblastic leukemia (ALL). Patients 51 …
treatment regimen for older adults with acute lymphoblastic leukemia (ALL). Patients 51 …
Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial
…, RM Stone, KK Ballen, J Rosenblatt… - The Lancet …, 2020 - thelancet.com
Background Increased aurora A kinase (AAK) expression occurs in acute myeloid leukaemia;
AAK inhibition is a promising therapeutic target in this disease. We therefore aimed to …
AAK inhibition is a promising therapeutic target in this disease. We therefore aimed to …
[HTML][HTML] Evaluation of a Pan-lysyl oxidase inhibitor, Pxs-5505, in myelofibrosis: a phase I, randomized, placebo controlled double blind study in healthy adults
J How, Y Liu, JL Story, DS Neuberg, K Ravid… - Blood, 2020 - Elsevier
BACKGROUND Myeloproliferative neoplasms (MPNs) are clonal stem cell neoplasms
characterized by terminal expansion of the myeloid cell lineage and include essential …
characterized by terminal expansion of the myeloid cell lineage and include essential …
[HTML][HTML] Phase II clinical trial of alisertib, an aurora a kinase inhibitor, in combination with induction chemotherapy in high-risk, untreated patients with acute myeloid …
…, MR Luskin, RM Stone, KK Ballen, J Rosenblatt… - Blood, 2018 - Elsevier
Background: Aurora kinases play essential roles in regulating cell division, and increased
expression has been noted in myelodysplastic syndromes (MDS) and acute myeloid leukemia …
expression has been noted in myelodysplastic syndromes (MDS) and acute myeloid leukemia …
Single-Cell Multiomics Analysis Reveals Potential Drivers of Response to the Anti-TIM3 Inhibitor Sabatolimab Combined with Azacitidine in MDS and CMML
…, B Arnold, J McGuire, T Chan, J Lombardi Story… - Blood, 2023 - ashpublications.org
Background The median survival for patients with newly diagnosed (ND) higher risk myelodysplastic
syndrome (MDS) and chronic myelomonocytic leukemia (CMML) remains poor. The …
syndrome (MDS) and chronic myelomonocytic leukemia (CMML) remains poor. The …
[HTML][HTML] Pregnancy outcomes, risk factors, and gestational cell count trends in pregnant women with essential thrombocythemia and polycythemia vera
CJ How, O Leiva, T Bogue, G Fell, M Bustoros… - Blood, 2019 - Elsevier
BACKGROUND Myeloproliferative neoplasms (MPNs) including essential thrombocythemia
(ET) and polycythemia vera (PV) are commonly diagnosed in the sixth decade, but as many …
(ET) and polycythemia vera (PV) are commonly diagnosed in the sixth decade, but as many …
Emergence of Chronic Myeloid Leukemia in Patients with Myeloproliferative Neoplasms: A Single-Institution Experience
KC Miller, J Lombardi Story, J Foster, JA Moran… - Blood, 2022 - ashpublications.org
Methods: We collected information on patients seen at Massachusetts General Hospital (MGH)
from January 1 2012 to January 1 2022 for CML occurring after an established diagnosis …
from January 1 2012 to January 1 2022 for CML occurring after an established diagnosis …
A nonrandomized phase I and biomarker trial of regorafenib in advanced myeloid malignancies
J How, S Ren, J Lombardi‐Story, M Bergeron… - …, 2022 - Wiley Online Library
We conducted a single‐center, open‐label, dose escalation, and expansion phase I trial of
the antiangiogenic multikinase inhibitor regorafenib in patients with advanced myeloid …
the antiangiogenic multikinase inhibitor regorafenib in patients with advanced myeloid …